Nasdaq
$1.94▲ 0.26%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $20.8MShares out 10.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 2d agoAfter-hours26.10.23 05:30DEF 14AOther#●●●
AYTU BIOPHARMA, INC
Aytu BioPharma will hold its annual meeting of stockholders on December 10, 2026, to vote on the election of directors, an amendment to the 2023 Equity Incentive Plan to add 500,000 shares, and the approval of the 2027 Employee Stock Purchase Plan. As of the record date of October 13, 2026, there are 10,868,208 shares of common stock outstanding and entitled to vote.…more
$1.94+0.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.22After-hours26.09.23 05:1410-KEarnings
AYTU BIOPHARMA, INC
Aytu BioPharma finalized the termination of its license and distribution agreement with Lannett for Metadate, effective June 23, 2026, resulting in the return of the New Drug Application (NDA) to Lannett. Additionally, the company adjusted its capital structure by converting a portion of the prefunded warrants issued in June 2025 into common stock and reclassifying the remaining warrants.…more
$1.94+0.26%vs prev closeView filingShare - 9.22After-hours26.09.23 05:058-KKey event
AYTU BIOPHARMA, INC
Aytu BioPharma reported fiscal 2026 fourth-quarter net revenue of $16.1 million and a net loss of less than $0.1 million, showing improved profitability compared to the prior year. While the new drug EXXUA generated $3.9 million in Q4 revenue, full-year revenue declined 13.3% to $57.6 million due to lower performance in the ADHD and pediatric portfolios.…more
$1.94+0.26%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.22After-hours26.09.23 05:06Bullish#●●●
Aytu BioPharma Q4 Sales Beat Estimates at $16.1M
Aytu BioPharma reported Q4 sales of $16.1 million, significantly exceeding the analyst consensus of $12.27 million. This result represents a 6.42% increase compared to the same period last year.…more
$1.94+0.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga